期刊文献+

中等剂量卡培他滨单药治疗老年转移性乳腺癌的临床观察 被引量:8

Moderate-dose Capecitabine Monotherapy in the Treatment of Elderly Patients with Metastatic Breast Cancer
下载PDF
导出
摘要 目的观察中等剂量卡培他滨单药治疗老年转移性乳腺癌的疗效和毒副反应。方法单药卡培他滨治疗39例老年转移性乳腺癌患者,每天2 000 mg·m-2,分2次口服,连用14 d,休息7 d,每21 d为1周期,直到疾病进展,最多行6周期治疗。结果全组39例老年转移性乳腺癌患者中,PR 9例,SD 25例,PD 5例,总有效率23.1%,肿瘤控制率87.2%,中位肿瘤进展时间7.6个月。毒副反应有:Ⅰ、Ⅱ度手足综合征14例(35.9%),Ⅰ、Ⅱ度骨髓抑制9例(23.1%),Ⅰ度腹泻2例(5.1%),Ⅰ度消化道反应1例(2.6%)。结论中等剂量卡培他滨单药治疗老年转移性乳腺癌安全有效,值得临床广泛推广。 Objective To observe the effect and toxicities of moderate-dose capecitabine monotherapy in the treatment of elderly patients with metastatic breast cancer. Methods Thirty-nine elderly patients with metastatic breast cancer were given with capecitabine:2000 mg· m-2,2 times a day, for 14 days, then rest 7 days,was repeated every 21 days, until disease progression, up to 6 cycles. Results PR was observed in the 9 patients, SD in the 25 patients, PD in the 5 patients, the total effective rate was 23. 1%, the tumor control rate was 87.2%, the median time to tumor progression was 7.6 months. The toxicities were:14 patients (35.9%) of I and II degree hand-foot syndrome,9 patients (23.1%) of I and II degree bone marrow suppression,2 patients (5.1%) of I degree diarrhea,only one patients (2.6%) of I degree digestive tract reaction. Conclusion Moderate-dose capecitabine monotherapy is effective and safe in the treatment of elderly patients with metastatic breast cancer, which is worth clinical promotion widely.
出处 《肿瘤基础与临床》 2015年第3期205-206,共2页 journal of basic and clinical oncology
关键词 中等剂量 卡培他滨 转移性乳腺癌 老年患者 moderate-dose capecitabine metastatic breast cancer elderly patients
  • 相关文献

参考文献6

  • 1Blum JL, Barrios CH, Feldman N, et al. Pooled analysis of individu- al patient data from capecitabine monotherapy clinical trials in lo- cally advanced ormetastatic breast cancer [ J ]. Breast Cancer Res Treat,2012,136 ( 3 ) :777 - 788. 被引量:1
  • 2Zielinski C, Gralow J, Martin M. Optimising the dose of capecit- abine in metastatic breast cancer: confused, clarified or confirmed? [J]. Ann Oncol,2010,21 ( 11 ) :2145 -2152. 被引量:1
  • 3Molina-Garrido M J, Mora-Rufete A, Guillen-Ponce C. Oral chemo- therapy in elderly women with metastatic breast cancer [ J ]. Anti- cancer Agents Med Chem ,2014,14 (5) :665 - 672. 被引量:1
  • 4严颖,任军,林晓琳,宛凤玲,邸立军.中等剂量卡培他滨单药治疗转移性乳腺癌的疗效及安全性[J].肿瘤防治研究,2012,39(9):1132-1135. 被引量:6
  • 5Bajetta E, Procopio G, Cello L, et al. ferent doses of capecitabine in the cancer in older women [ J ]. J Clin -2161. Safety and efficacy of two dif- treatment of advanced breast Oncol, 2005,23 ( 10 ) : 2155. 被引量:1
  • 6Zhou Y, Peng L2, Li Y1, et al. Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syn- drome : A meta-analysis [ J ]. Biomed Rep,2013,1 (6) : 873 - 878. 被引量:1

二级参考文献16

  • 1Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients[J]. Cancer,2001,92(7) :1759-68. 被引量:1
  • 2Reichardt P,Von Minckwitz G,Thuss-Patience PC, et al. Mul- ticenter phase Ⅱ study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy[J]. Ann Oncol, 2003, 14 (8) 1227-33. 被引量:1
  • 3Largillier R, Fumoleau P, Clippe C, et al. Capecitabine (X) monotherapy after anthracycline and taxane failure in meta static breast cancer (MBC) : long-term survival data[J]. Ann Oncol, 2006,17 (Suppl 9) : ix69-ix92. 被引量:1
  • 4Mavroudis D, Ardavanis A,Boukovinas l,et al. A multicenter randomized study comparing vinorelbine plus gemcitabine ver- sus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and an- thracycline chemotherapy:a preliminary report[J]. J Clin On- col, 2/)(16,24 (18S) : 658. 被引量:1
  • 5Zielinski C, Gralow J, Martin M. Optimising the dose of capecit abine in metastatic breast cancer: confused, clarified or confirmed?[J]. Ann Oncol,2010,21 (11):2145-52. 被引量:1
  • 6Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5 fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate,in human cancer xenografts[J]. Biochem Pharma- co1,1998,55(7) :1091-7. 被引量:1
  • 7Sezgin C, Kurt E,Evrensel T, et al. Efficacy of lower dose capecit abine in patients with metastatic breast cancer and factors influen cing therapeutic response and outcome[J]. South Med J, 2007,100 (1):27-32. 被引量:1
  • 8Hennessy BT, Gauthier AM, Michaud LB, et al. Lower dose capecitabine has a more favorable therapeutic index in meta- static breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature[J]. Ann Oncol,2005,16(8):1289-96. 被引量:1
  • 9Yap YS,Kendall A,Walsh G,et al. Clinical efficacy of capecit- abine as first-line chemotherapy in metastatic breast cancer how low can you go?[J]. Breast,2007,16(4) :420- 4. 被引量:1
  • 10Kaufmann M, Maass N, Costa SD, et al. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial[J]. Eur J Cancer, 2010,46(18) :3184-91. 被引量:1

共引文献5

同被引文献40

引证文献8

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部